Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections

Antiviral Therapy

Volumn 16, Issue 5, 2011, Pages 733-740

  Fuehner, Thomas ^a   Dierich, Martin ^a   Duesberg, Christoph ^a   DeWall, Claudia ^a   Welte, Tobias ^a   Haverich, Axel ^a   Warnecke, Gregor ^a   Simon, Andre R ^b   Gottlieb, Jens ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PREDNISOLONE; RIBAVIRIN; STEROID;

ADULT; ANALYTICAL PARAMETERS; ANEMIA; ARTICLE; BRONCHIOLITIS OBLITERANS; BRONCHOSCOPY; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DYSPNEA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FUNCTIONAL STATUS; GRAFT RECIPIENT; HEART LUNG TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOXIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LEUKOPENIA; LOWER RESPIRATORY TRACT INFECTION; LUNG INFILTRATE; LUNG LAVAGE; LUNG TRANSPLANTATION; MAINTENANCE DRUG DOSE; MALE; NOSE SMEAR; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARAMYXOVIRUS INFECTION; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF MONITORING; SPIROMETRY; SPUTUM; THERAPY EFFECT; THORAX RADIOGRAPHY; THROAT CULTURE; TREATMENT DURATION; TREATMENT PLANNING; VIRUS DETECTION; WHEEZING;

ADULT; AMBULATORY CARE FACILITIES; ANTIVIRAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CONTROL GROUPS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PARAMYXOVIRIDAE INFECTIONS; PROSPECTIVE STUDIES; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTIONS; RIBAVIRIN; SCHOOLS, MEDICAL; SPIROMETRY; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 80052426269     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1811     Document Type: Article

References (30)

1. Billings J.L., Hertz M.I., Wendt C.H. Community respiratory virus infections following lung transplantation. Transpl Infect Dis 2001; 3:138-148. (Pubitemid 32756696)
2. Kumar D., Husain S., Chen M.H., et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89:1028-1033.
3. Fishman J.A. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601-2614. (Pubitemid 350294226)
4. Palmer S.M., Jr., Henshaw N.G., Howell D.N., et al. Community respiratory viral infection in adult lung transplant recipients. Chest 1998; 113:944-950. (Pubitemid 28216436)
5. Khalifah A.P., Hachem R.R., Chakinala M.M., et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004; 170:181-187. (Pubitemid 38925165)
6. Hopkins P., McNeil K., Kermeen F., et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med 2008; 178:876-881.
7. Kumar D., Erdman D., Keshavjee S., et al. Clinical impact of community acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005; 5:2031-2036. (Pubitemid 41039882)
8. Gottlieb J., Schulz T.F., Welte T., et al. Community-acquired respiratory viral infections in lung transplant recipients: A single season cohort study. Transplantation 2009; 87:1530-1537.
9. Milstone A.P., Brumble L.M., Barnes J., et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 2006; 28:131-137. (Pubitemid 44914270)
10. Weinberg A., Zamora M.R., Li S., et al. The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients. J Clin Virol 2002; 25:171-175. (Pubitemid 35287241)
11. Glanville A.R., Scott A.I., Morton J.M., et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005; 24:2114-2119. (Pubitemid 41814734)
12. McCurdy L.H., Milstone A., Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant 2003; 22:745-753. (Pubitemid 36842926)
13. Raza K., Ismailjee S.B., Crespo M., et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant 2007; 26:862-864. (Pubitemid 47199078)
14. Shima T., Yoshimoto G., Nonami A., et al. Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient. Int J Hematol 2008; 88:336-340.
15. Ison M.G., Michael M.G. AST infectious diseases community of practice. RNA respiratory viral infections in solid organ transplant recipients. Am J Transplant 2009; 9:166-172.
16. Miller M.R., Hankinson J., Brusasco V., et al. Standardisation of spirometry. Eur Respir J 2005; 26:319-338. (Pubitemid 41079078)
17. Estenne M., Maurer J.R., Boehler A., et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297-310. (Pubitemid 34224094)
18. Snell G.I., Boehler A., Glanville A.R., et al. Eleven years on: A clinical update of key areas of the 1996 lung allograft rejection working formulation. J Heart Lung Transplant 2007; 26:423-430. (Pubitemid 46602012)
19. Tazelaar H.D. Perivascular inflammation in pulmonary infections: Implications for the diagnosis of lung rejection. J Heart Lung Transplant 1991; 10:437-441.
20. Nichols W.G., Gooley T., Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: The Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001; 7 Suppl 1:11S-15S. (Pubitemid 33734763)
21. Boeckh M., Englund J., Li Y., et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infections in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 44:245-249. (Pubitemid 46079989)
22. Schleuning M., Buxbaum-Conradi H., Jager G., et al. Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogenic hematopoietic stem cell transplants. Hematol J 2004; 5:135-144. (Pubitemid 38519263)
23. Pelaez A., Lyon G.M., Force S.D., et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant 2009; 28:67-71.
24. Hofmann W.P., Herrmann E., Sarrazin C., et al. Ribavirin mode of action in chronic hepatitis C: From clinical use back to molecular mechanisms. Liver Int 2008; 28:1332-1343.
25. Thomas E., Feld J.J., Li Q., et al. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011; 53:32-41.
26. Liu V., Dhillon G.S., Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis 2010; 12:38-44.
27. Goldstein R.A., Rohatgi P.K., Bergofsky E.H., et al. Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis 1990; 142:481-486. (Pubitemid 20235965)
28. Alvarez R., Elbashir S., Borland T., et al. RNA interferencemediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother 2009; 53:3952-3962.
29. Zamora M.R., Budev M., Rolfe M., et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011; 183:531-538.
30. Nicas M., Nazaroff W.W., Hubbard A. Toward understanding the risk of secondary airborne infection: Emission of respirable pathogens. J Occup Environ Hyg 2005; 2:143-154. (Pubitemid 40397039)